Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) reported that the company has appointed Gregory Naeve, Ph.D., as Chief Business Officer. Dr. Naeve will lead portfolio and product strategy and business development for the firm.
Rick Fair, the CEO and President of Bellicum, reported that they are thrilled to welcome a leader of Dr. Naeve’s caliber and experience as they intend to expand their pipeline and seek strategic associations to leverage their technology platform. Dr. Naeve brings a remarkable track record of outlining immuno-oncology portfolio strategy and executing it through successful alliances. His contributions will be significant as they look to capitalize on their portfolio of controllable cell therapy technologies.
Commenting on his new role, Dr. Naeve expressed that it is becoming gradually clear how vital innovations are to advancing TCR and CAR T candidates into more ailments, especially solid tumors. He will work together with Bellicum’s R&D and management teams to advance these innovative technologies, which possesses potential to transform the world of cellular therapy.
Prior to Bellicum, Dr. Naeve was associated with Pfizer Inc. (NYSE:PFE) where he was as the ImmunoOncology and Cell Therapy Lead for company’s External Research and Development segment.
During his tenure, he was a member of the executive team responsible for recognizing and implementing numerous strategic associations in Pfizer’s ImmunoOncology portfolio. Prior to Pfizer, Dr. Naeve was a Principal of “The Column Group”, which is a venture capital company focused on investing in and building unique biotechnology firms. Early in his career, he served on research roles at Amgen and Neurocrine Biosciences.
The Compensation Committee of Bellicum’s Board has permitted inducement awards to Dr. Naeve, effective from the joining date. These inducement awards comprise of a stock option to buy up to 130,000 shares of the firm’s common stock as well as a restricted stock unit in lieu for 15,000 shares.